EULAR 2023 Lupus Highlights
Rheumnow Podcast
00:00
CAR T Therapy in Connective Tissue Diseases
This was presented initially by Georg Shet, the first seven patients at the ACR meeting. Now it's anti-synthetase syndrome. That's Jo1 positive mass status. They've now treated four patients with scleroderma. So one could expect in these patients a high dry clearance in urinary losses. Maybe the actual biologically active dose of bulimum is not as high when the disease is active and gives a lot of protein area. But these are all speculations. It is, of course, important to really perform experiments and to look at the differential effects of different dose of the bulimum on bases.
Transcript
Play full episode
